Therapix Biosciences Names New CEO

October 22, 2014 | Therapix Biosciences announced that the company has selected a new CEO, Jan Turek. According to the company, the new CEO will be responsible for growing the company, seeing to the acquisition and investment in cannabinoid-focused companies and technologies. According to Therapix Chairman Dr. Ascher Shmulewitz, “Jan will play an integral role in executing our new strategy, and we are thrilled that he has agreed to join our team as CEO. He has an impressive track record spanning more than three decades, and I am confident that the company is optimally positioned to emerge as a leader in this exciting therapeutic area.” Therapix is a specialty pharmaceutical company focused on synthetic cannabinoid-based therapies.